GlobeNewswire Inc.··Not SpecifiedOcular Therapeutix Plans June Investor Day Amid Promising AMD Trial Data
Ocular Therapeutix schedules June 17 investor day in NYC while reporting positive Week 52 data from SOL-1 Phase 3 trial of AXPAXLI for wet AMD treatment.
OCULPhase 3 trialInvestor Day